Eurepa® (Repaglinide Tablets) – 0.5 mg | 1 mg | 2 mg

Eurepa is a fast-acting repaglinide tablet that controls post-meal blood sugar spikes in Type 2 diabetes.

Eurepa® (Repaglinide Tablets) is an oral antidiabetic medicine belonging to the meglitinide class, used for the management of type 2 diabetes mellitus. It works by stimulating rapid insulin release from the pancreas, helping control post-meal blood glucose levels.

Eurepa is commonly prescribed for patients who require flexible meal-time glucose control and may be used alone or in combination with other antidiabetic agents such as metformin. Its quick onset and short duration of action make it suitable for individualized diabetes management.

Available strengths include 0.5 mg, 1 mg, and 2 mg, allowing dose adjustment based on patient requirements and physician guidance.

Medicina Overseas supplies Eurepa® tablets for international export, supporting pharmacies, hospitals, distributors, and bulk buyers with reliable sourcing and export-compliant documentation.

⚠️ Prescription medicine. To be used only under medical supervision.

✅ KEY USES (OPTIONAL – IMPROVES CONVERSION)

• Management of type 2 diabetes mellitus

• Control of post-prandial (after-meal) blood glucose

• Short-acting oral antidiabetic therapy

• Suitable for combination diabetes treatment plans